ClinicalTrials.gg
RecruitingNCT06565078Updated Aug 7, 2026

A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency

An observational study in Primary Immunodeficiency Diseases (PID), sponsored by Takeda. Recruiting at 1 site in Japan. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Takeda · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
100
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Primary Immunodeficiency Diseases by Takeda — 2 open to participants now, 3 under way, 1 of them phase 3. Primary Immunodeficiency Diseases · Takeda.

Started
2025
the only one that year
Observational
4 of 23
1 open now
Registered
21st of 23
by date

Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, this one is the only one that started in 2025, is one of 4 observational ones, and was the 21st registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 23 studies in Primary Immunodeficiency Diseases by Takeda are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Primary Immunodeficiency Diseases by Takeda, or all of them as a file.
02

Study summary

This study is a retrospective database study in Japan to evaluate the safety of Immune Globulin Subcutaneous (Human), 20% Solution in participants with primary immunodeficiency disease (PID). This survey will conduct in use of medical database called PIDJ2.

03

Conditions studied

  • Primary Immunodeficiency Diseases (PID)

Keywords

  • Primary immunodeficiency disease
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The population of this survey are all participants who meet the inclusion/exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with primary immunodeficiency (PID) enrolled in the PID patient registry.
  2. Participant for whom study drug is entered in the therapeutic drug field on the data set.
  3. Participant who is entered the intractable disease diagnosis corresponding to PID in the intractable disease information field.
  4. Participant for whom the presence or absence of adverse events has been entered in the column of adverse events.

Exclusion criteria

Exclusion Criteria:

  1. Participant for whom study drug has not been entered in the drug name in the medical history field during the period from January 24, 2024 to January 23, 2029.
  2. Participant who is not entered the intractable disease diagnosis corresponding to PID in the intractable disease information field.
  3. Participant for whom the presence or absence of adverse events has not been entered in the column of adverse events.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Immune Globulin Subcutaneous (Human), 20% Solution

    Participants with primary immunodeficiency disease who received Immune Globulin Subcutaneous (Human) 20% infusion in accordance with package insert.

    Drug: Immune Globulin Subcutaneous (Human), 20% Solution

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience Anaphylactic Reaction as an Adverse Event (AE)

    An AE is defined as any untoward event that occurred in a participant after the first dose of study drug, which does not necessarily have a causal relationship with primary immunodeficiency disease. Number of participants who experience anaphylactic reaction as an AE will be reported.

    Time frame: From initial registration in the database or first dose of study drug, whichever came late, up to end date of data period (up to 5 years)

  2. Number of Participants Who Experience Thromboembolism as an AE

    An AE is defined as any untoward event that occurred in a participant after the first dose of study drug, which does not necessarily have a causal relationship with primary immunodeficiency disease. Number of participants who experience thromboembolism as an AE will be reported.

    Time frame: From initial registration in the database or first dose of study drug, whichever came late, up to end date of data period (up to 5 years)

  3. Number of Participants Who Experience Aseptic Meningitis as an AE

    An AE is defined as any untoward event that occurred in a participant after the first dose of study drug, which does not necessarily have a causal relationship with primary immunodeficiency disease. Number of participants who experience aseptic meningitis as an AE will be reported.

    Time frame: From initial registration in the database or first dose of study drug, whichever came late, up to end date of data period (up to 5 years)

07

Study locations

1 of 1 sites recruiting
  • Takeda selected site
    Tokyo, Tokyo, Japan
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Mar 2030, 61 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2024
First posted
Aug 21, 2024
StartActual
Feb 17, 2025
Primary completionEst.
Mar 31, 2030
CompletionEst.
Mar 31, 2030
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06565078
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Aug 21, 2024
Start date
Feb 17, 2025
Primary completion
Mar 31, 2030 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Aug 7, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion